Current Illinois CancerCare Clinical Trials

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Study Number: A031702

Study Summary:
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Status: Open

Just In Time Trial

Study available for the following diagnoses:
Small cell carcinoma of the bladder
Plamacytoid urothelial carcinoma
Penile
Sarcomatoid renal cell carcinoma
Sarcomatoid urothelial carcinoma
Renal medullary carcinoma
Miscellaneous histologic variants of urothelial carcinoma

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Alyssa, 309-243-3626, awagner@illinoiscancercare.com

Study Link

« Search Again